Cytisine, a nicotine substitute, more than triples a person\'s chances of quitting smoking for at least a year, British and Polish researchers say. Lead author Robert West, director of tobacco studies at the Cancer Research UK Health Behavior Research Center at University College London said co-investigator Witold Zatonski, a doctor at the Cancer Center and Institute of Oncology in Warsaw, Poland, had been telling him for years that \"there was this pill available in Eastern Europe that he believed was effective and cost next to nothing,\" to help smokers quit. The drug, sold under the name Tabex to Eastern European countries for more than 40 years, binds with high affinity to the nicotinic acetylcholine receptor, controlling nicotine dependence, Medscape Medical News reported. Although Tabex was withdrawn by some countries when they joined the European Union, it is still available in Poland for about $15 for a treatment course and for about $6 in Russia, Zatonski said. A randomized, controlled trial of more than 740 smokers from Poland, who smoked 10 or more cigarettes a day for 25 days. The study, published in the New England Journal of Medicine, showed significantly more participants receiving cytisine maintained smoking abstinence at six months and one year compared with those receiving a placebo.
GMT 14:01 2018 Thursday ,30 August
Expat with rare heart disorder gets life-saving surgeryGMT 00:18 2018 Tuesday ,23 January
Boy with 10-pound tumour on face diesGMT 21:23 2018 Monday ,22 January
All set for first global medical tourism conference in DubaiGMT 22:46 2018 Sunday ,21 January
Second face transplant for FrenchmanGMT 07:51 2018 Saturday ,20 January
Trio aquitted of negligence in Canada railway disasterGMT 10:57 2018 Thursday ,18 January
Breastfeeding for 6 months cuts diabetes risk in half: studyGMT 16:10 2018 Wednesday ,17 January
Child mummy in Italy had hepatitis, not smallpoxGMT 18:36 2018 Tuesday ,16 January
Greece strikes cause transport chaos, healthcare delays

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor